Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Avadel Pharmaceuticals plc

$21.64

-0.02 (-0.09%)

D 33Pipeline Score Richly Valued Pharma · Clinical
Market Cap
2.12 B
EPS
0.00
P/E Ratio
-
Value Trade
758.22 M
SEC Financials
Q3 2025

  • Dilution Risk

    5%

  • Revenue

    77.47 M

  • R&D Expenses

    27.01 M

  • Total Assets

    199.45 M

  • Total Liabilities

    101.22 M

  • Equity

    98.22 M

  • D/E Ratio

    12,345

0.19 %
Week
0.7 %
1 Month
13.54 %
3 Month
59.82 %
6 Month
133.69 %
5 Year
80.33 %
All Time
Cash Data
Profitable

  • Cash Position

    91.58 M

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    Nov 4, 2025
Overview
Volume
35.02 M
52 Week Range
6.38 - 23.57
% held by Insiders
5.27 %
% held by Institutions
75.91 %
Enterprise Value
2.06 B
Total Shares
97.14 M
Short %
2.61 %
Float Shares
88.49 M
Company Description
Founded:2015

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Approval Decision example
LUMRYZ10 idiopathic hypersomnia in adults
Orphan
NDA
—

Subscribe to access the data.

Small Molecules
Nervous System
LUMRYZ10 idiopathic hypersomnia in adults
Orphan
NDA
—

Subscribe to access the data.

Small Molecules
Nervous System
LUMRYZ10 idiopathic hypersomnia in adults
Orphan
NDA
—

Subscribe to access the data.

Small Molecules
Nervous System
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D33
Pipeline Score
$211M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 41%
Small Cap
(rank 539 of 912)
Percentile Rank
Avadel Pharmaceuticals plc faces pipeline headwinds (33/100), with $324M risk-adjusted pipeline value, led by FT218 in Narcolepsy (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
FT218
Small molecule		Excessive Daytime SleepinessPhase 3NCT0272074450% $324M COMPLETED 212 - -Mar 25, 2020 -Mar 22, 2022
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
LUMRYZ
Orphan
narcolepsy
Phase 3
2025-09-05

statistically significant and clinically meaningful improvements in the three co-primary endpoints

Read More

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

Read More
LUMRYZ
Orphan
narcolepsy
Phase 3
2025-09-05

statistically significant and clinically meaningful improvements in the three co-primary endpoints

Read More

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

Read More
LUMRYZ
Orphan
narcolepsy
Phase 3
2025-09-05

statistically significant and clinically meaningful improvements in the three co-primary endpoints

Read More

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension at World Sleep 2025

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in AVDL
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
AVDL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How AVDL ranks across every disease it competes in
Competitive Position is a premium feature
See how AVDL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial